ZEB1/NuRD complex suppresses TBC1D2b to stimulate E-cadherin internalization and promote metastasis in lung cancer.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
12 11 2019
Historique:
received: 01 03 2019
accepted: 29 09 2019
entrez: 14 11 2019
pubmed: 14 11 2019
medline: 28 2 2020
Statut: epublish

Résumé

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide, due in part to the propensity of lung cancer to metastasize. Aberrant epithelial-to-mesenchymal transition (EMT) is a proposed model for the initiation of metastasis. During EMT cell-cell adhesion is reduced allowing cells to dissociate and invade. Of the EMT-associated transcription factors, ZEB1 uniquely promotes NSCLC disease progression. Here we apply two independent screens, BioID and an Epigenome shRNA dropout screen, to define ZEB1 interactors that are critical to metastatic NSCLC. We identify the NuRD complex as a ZEB1 co-repressor and the Rab22 GTPase-activating protein TBC1D2b as a ZEB1/NuRD complex target. We find that TBC1D2b suppresses E-cadherin internalization, thus hindering cancer cell invasion and metastasis.

Identifiants

pubmed: 31719531
doi: 10.1038/s41467-019-12832-z
pii: 10.1038/s41467-019-12832-z
pmc: PMC6851102
doi:

Substances chimiques

Cadherins 0
Co-Repressor Proteins 0
GTPase-Activating Proteins 0
TBC1D2 protein, human 0
Zinc Finger E-box-Binding Homeobox 1 0
Mi-2 Nucleosome Remodeling and Deacetylase Complex EC 3.5.1.98
rab GTP-Binding Proteins EC 3.6.5.2

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5125

Subventions

Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Organisme : NCI NIH HHS
ID : R37 CA214609
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Organisme : U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI)
ID : R37 CA214609-01A1
Pays : International

Références

Nat Neurosci. 2016 Aug;19(8):1060-72
pubmed: 27294509
Ann Surg Oncol. 2014 Aug;21(8):2642-9
pubmed: 24700299
Nature. 2007 Apr 19;446(7138):882-7
pubmed: 17392792
Clin Chest Med. 2011 Dec;32(4):703-40
pubmed: 22054881
Traffic. 2010 Apr;11(4):491-507
pubmed: 20070612
Cell Cycle. 2015;14(4):481-7
pubmed: 25607528
J Clin Invest. 2016 Sep 1;126(9):3219-35
pubmed: 27500490
BMC Mol Biol. 2009 Sep 15;10:89
pubmed: 19754958
Mol Cell Biol. 1999 Dec;19(12):8581-90
pubmed: 10567582
Nat Rev Cancer. 2007 Jun;7(6):415-28
pubmed: 17508028
Cold Spring Harb Perspect Biol. 2013 Dec 01;5(12):a016949
pubmed: 24296170
Cancers (Basel). 2013 Apr 03;5(2):334-56
pubmed: 24216980
Genome Biol. 2009;10(3):R25
pubmed: 19261174
Oncogene. 2010 Jun 17;29(24):3490-500
pubmed: 20418909
Cell Rep. 2016 Jun 28;16(1):133-147
pubmed: 27320920
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
Cell Mol Life Sci. 2015 Jul;72(13):2491-507
pubmed: 25796366
J Biol Chem. 2005 Oct 21;280(42):35477-89
pubmed: 16061479
Nat Commun. 2016 Feb 15;7:10498
pubmed: 26876920
Nat Commun. 2014 Oct 28;5:5241
pubmed: 25348003
PLoS One. 2009;4(4):e5401
pubmed: 19404390
Mol Biol Cell. 2014 Aug 15;25(16):2365-74
pubmed: 24966173
Mol Cell Proteomics. 2015 Jul;14(7):1781-95
pubmed: 25900982
Gene. 2016 May 15;582(2):112-21
pubmed: 26869315
Genes Dev. 2009 Sep 15;23(18):2140-51
pubmed: 19759262
Nat Cell Biol. 2014 Sep;16(9):864-75
pubmed: 25086746
J Clin Invest. 2016 Nov 1;126(11):4237-4249
pubmed: 27760049
EMBO J. 2005 Jul 6;24(13):2367-78
pubmed: 15920470
Cancer Cell. 2015 Jun 8;27(6):822-36
pubmed: 26028330
Nat Rev Genet. 2016 Aug;17(8):487-500
pubmed: 27346641
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
EMBO J. 2012 Feb 1;31(3):593-605
pubmed: 22139358
Curr Protoc Protein Sci. 2013 Nov 05;74:19.23.1-19.23.14
pubmed: 24510646
Genome Med. 2018 Feb 27;10(1):16
pubmed: 29486777
Hum Mol Genet. 2008 Apr 15;17(8):1175-83
pubmed: 18182442
Mol Biol Cell. 2004 Aug;15(8):3758-70
pubmed: 15181155
EMBO J. 1999 Sep 15;18(18):5073-84
pubmed: 10487759
Dev Cell. 2013 Apr 15;25(1):15-28
pubmed: 23562278
Oncogene. 2016 Jan 14;35(2):173-86
pubmed: 25798833
Cell. 2009 Nov 25;139(5):871-90
pubmed: 19945376
Cell Rep. 2015 Sep 22;12(11):1816-30
pubmed: 26344766
J Cell Biol. 2012 Mar 19;196(6):801-10
pubmed: 22412018
Exp Cell Res. 2017 Aug 1;357(1):9-16
pubmed: 28433697
Nat Rev Cancer. 2011 Jul 07;11(8):588-96
pubmed: 21734722
Mol Cell Biol. 2006 Apr;26(7):2595-614
pubmed: 16537905
PLoS One. 2010 Jan 13;5(1):e8697
pubmed: 20084174
Curr Biol. 2010 Feb 9;20(3):198-208
pubmed: 20116244
EMBO Mol Med. 2015 Apr 14;7(6):831-47
pubmed: 25872941
Elife. 2014 Aug 27;3:e03346
pubmed: 25163748
Methods Mol Biol. 2015;1298:295-304
pubmed: 25800852
Science. 2004 Oct 22;306(5696):636-40
pubmed: 15499007
Nat Cell Biol. 2014 Feb;16(2):167-78
pubmed: 24413434
Nat Methods. 2011 Jan;8(1):70-3
pubmed: 21131968

Auteurs

Roxsan Manshouri (R)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Etienne Coyaud (E)

Department of Medical Biophysics, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, M5S 1A1, Canada.

Samrat T Kundu (ST)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

David H Peng (DH)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Sabrina A Stratton (SA)

Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Kendra Alton (K)

Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Rakhee Bajaj (R)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Jared J Fradette (JJ)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Rosalba Minelli (R)

Department of Cancer Genomics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Michael D Peoples (MD)

Department of Cancer Genomics, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Alessandro Carugo (A)

Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Fengju Chen (F)

Department of Medicine and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.

Christopher Bristow (C)

Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Jeffrey J Kovacs (JJ)

Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Michelle C Barton (MC)

Department of Epigenetics and Molecular Carcinogenesis, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Tim Heffernan (T)

Institute for Applied Cancer Science, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.

Chad J Creighton (CJ)

Department of Medicine and Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, USA.

Brian Raught (B)

Department of Medical Biophysics, Princess Margaret Cancer Centre, University of Toronto, Toronto, ON, M5S 1A1, Canada.

Don L Gibbons (DL)

Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. dlgibbon@mdanderson.org.
Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. dlgibbon@mdanderson.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH